Dyslipidemia is a condition characterized by abnormally elevated cholesterol or lipids (fats) in the blood. Dyslipidemias may be Primary that is genetic or Secondary, which is caused by lifestyle and other factors. Raised cholesterol increases the risks of heart disease and stroke.
The market is primarily driven by increase in prevalence of dyslipidemia worldwide, increasing awareness, and changing lifestyle. However, high drug prices acts as a major barrier to market growth with statins being the most expensive lipid-lowering medicines.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
